MaxiVAX SA

MaxiVAX was founded by Nicolas Mach (Oncology, HUG in Geneva) and Bernard Mach (ex-University of Geneva & Co-founder of Biogen). Some of its key technology is derived from Patrick Aebischer (EFPL, Lausanne). MaxiVAX develops active immunization for personalized anti-cancer vaccination. The company has successfully completed a first-in-man clinical study (Phase 1), targeting patients with a variety of solid tumors, including pancreas, colon, head and neck, chordoma, prostate and ovarian.A total of 15 patients, all having failed multiple standard therapies, were treated in the study.